🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMOBreast23 Check out our poster showing that patients switching to ER-low phenotype from early to advanced BC esperience even poorer prognosis than those switching to pure TNBC. We need to grant ER-low pts access to TNBC trials and treatment algorithms

Can we omit anthracyclins for TNBC early breast cancer? Meta analysis . Non inferior for recurrence but not for over all mortality. ESMO - Eur. Oncology #ESMOBreast23

🧠 mets Vs matched primary Breast cancer: more HER2-enriched subtypes, more ERBB2 expression, less ESR1 expression Check out poster 253 today at #ASCO2023 ! #bcsm #oncoalert

As #ASCO23 is closing, I am delighted to share our latest #IJC paper Radiological response of breast cancer leptomeningeal mts by RANO criteria is associated with overall survival #bcsm #brainmets A step forward in taking care of our patients! #Oncoalert doi.org/10.1002/ijc.34…

Super proud that our work on a prognostic model for OS based on RCB + RD-TILs after NAT in HER2+ BC is finally out on Clinical Cancer Research!! ⬆️ TILs on RD —> worse OS ⬆️ RCB-TIL scores —> worse OS Maria Vittoria Dieci Gaia Griguolo Michele Bottosso aacrjournals.org/clincancerres/…

DAISY trial (TDXD) Nature Medicine : 29% OR in pts Her2=0 but only 4 months PFS Her2=0: pts w ultralow ERBB2 by RT-PCR present ORs No uptake of TDXD by tumor in Her2=0 vs uptake in Her2+ No quantitative change of immune cells drg TDXD Uptake of TDXD in 4/6 samples at resistance

Finally out on Journal of Clinical Oncology the 10-Year update of the ShortHER trial: proud and honored to be part of this relevant work Maria Vittoria Dieci ascopubs.org/doi/full/10.12…

🧠 Can we non invasively assess HER2 status of breast cancer brain metastases using radiomics? #bcsm #brainmets Check out poster 479P at today's poster session at #ESMO2023 #ESMO23 IOV - Istituto Oncologico Veneto Università di Padova Maria Vittoria Dieci OncoAlert

In HR+HER2- early breast cancer, high genomic risk tumors by OncotypeDX present higher levels of TILs (more than 10%) ! -> potential clinical implications? Great minioral presentation today by Federica Miglietta of our group at #ESMO23 ! #bcsm Maria Vittoria Dieci Università di Padova IOV - Istituto Oncologico Veneto

At the INNOVATORS - after ESMO meeting, Michele Bottosso discusses on Li-Fraumeni sdr, firstly described here ⬇️ by Frederick Li and Joseph Fraumeni in 1969. acpjournals.org/doi/abs/10.732… Alessandra Gennari MD PhD valentina

We are so glad to share our immuno-genomic model for HR+/HER2- eBC based on the integrated evaluation of Recurrence Score & TILs. 💡Just out on European Journal of Cancer Maria Vittoria Dieci doi.org/10.1016/j.ejca…

ERlow = ERneg BC from molecular and immune perspective. Come to visit our poster P01-03-09. Find us in the “Triple Negative” poster row: a sign that times are finally mature for a change? Gaia Griguolo Federica Miglietta Università di Padova IOV - Istituto Oncologico Veneto #SABCS23 OncoAlert

Out in ESMO Open our review on precision medicine in #breastcancer: 📍milestones of genomics to predict drug sensitivity 📍new dimensions of cancer biology 📍future directions of precision medicine Fernanda Mosele FabriceAndre Stefan Michiels Gustave Roussy doi.org/10.1016/j.esmo…

TP53-associated early breast cancer 227 pts, mFU: 70 mo mAge➡️37 HR+/HER2-➡️40.9% HR+/HER2+➡️34.4% 5y RFS (HR+/HER2)➡️61.1%!! 5y radiation-induced sarcoma➡️4.8%‼️ Quite an informative analysis. Congrats to all the researchers OncoAlert JNCI academic.oup.com/jnci/article-a…

A lot of discussion these days around ER-low. We present data in >1200 MBC including prognosis, switch from primary tumor, TILs and data from the TONIC trial! Stop at poster board 78! #ASCO24 Federica Miglietta MarleenKokLab

Check Poster 558 #ASCO24 ! - PAM 50 and TILs/immune signatures capture only partially overlapping information on HR+/HER 2 BC biology Are pts with Basal-like HR+/HER 2 BC and high TILs r ideal candidates for neoadjuvant ICI+chemo? #bcsm Maria Vittoria Dieci OncoAlert TILs Working Group

❓ How can gene expression assays guide the choice of adjuvant endocrine therapy in #breastcancer? 👉🏻 Check out our review in Clinical Cancer Research Gaia Griguolo Maria Vittoria Dieci Federica Miglietta aacrjournals.org/clincancerres/…

As we are all going back home from #SABCS24 , check out out spotlight poster on actionable alterations in breast cancer brain metastases if you missed it! High rate of BRCA1/BRCA2/PALB2 alterations and of PIK3CA/PTEN alterations! OncoAlert

Multi-institutional study (779 pts with BC 🧠 mets over 22 years) shows: 🔹 Changes in RT (SRS ↑; WBRT ↓) 🔹 Increase in anti-HER2 tx 🔹 OS unchanged overall, but… improvement in HR-/HER2+ BC mOS 8.7 → 23.7 months (p=0.002) rdcu.be/eeS9D OncoAlert Michele Bottosso

#ESMOBreast25 In eTNBC achieving pCR, TILs maintain prognostic value. Low TILs and cN+ identify a subgroup of patients at worse prognosis despite pCR: space for escalation? Great work by Davide Massa Maria Vittoria Dieci from our group! Great international collaboration! OncoAlert